glp-1 agonist drugs oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Which of the following GLP-1
Description
That benchmark is largely settled
Accessed: Oct
[DOI] [PubMed] [Google Scholar] 36
Therefore, in the past GIP has been considered an unappealing therapeutic target for T2DM
Lean body mass remained mostly stable, so muscle loss was minimal and fat loss was maximized
